_id
6919e7c23c536f8df231820e
Ticker
FARN.LSE
Name
Faron Pharmaceuticals Oy
Exchange
LSE
Address
Joukahaisenkatu 6 B, Turku, Finland, 20520
Country
UK
Sector
Healthcare
Industry
Biotechnology
Currency
GBX
Website
https://faron.com
Description
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, it develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Last Close
1800000
Volume
6
Current Price
183.6
Change
0
Last Updated
2025-12-30T10:53:52.647Z
Image
https://logo.clearbit.com/faron.com
Ipo Date
-
Market Cap
221893936
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.986
Sentiment Sources
2
Rating
4
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
-
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
5954.5
Operating Income
-5954.5
Interest Expense
3756.5
Pretax Income
-9711.5
Net Income
-9711.5
Eps
-0.09042112417716451
Dividends Per Share
-
Shares Outstanding
113902670
Income Tax Expense
-
EBITDA
-5879
Operating Margin
-
Total Other Income Expense Net
-3757
Cash
13532000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
14805000
Property Plant Equipment
250000
Total Assets
16204000
Payables
5634000
Short Term Debt
961000
Long Term Debt
21309000
Total Liabilities
32450000
Equity
-16246000
Bs_currency_symbol
EUR
Depreciation
75.5
Change In Working Capital
36.5
Cash From Operations
-5205
Capital Expenditures
0
Cash From Investing
-50.5
Cash From Financing
7336.5
Net Change In Cash
-
Cf_currency_symbol
-
PE
-
PB
-1.2137874430629076
ROE
0.05977779145635849
ROA
-0.059932732658602814
FCF
-5205
Fcf Percent
-
Piotroski FScore
1
Health Score
24
Deep Value Investing Score
0.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
0.5
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
0.5
Quality Investing Score
0.5
Value Investing Score
0.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
5954.5
Quarters > 0 > income Statement > operating Income
-5954.5
Quarters > 0 > income Statement > interest Expense
3756.5
Quarters > 0 > income Statement > pretax Income
-9711.5
Quarters > 0 > income Statement > net Income
-9711.5
Quarters > 0 > income Statement > eps
-0.09042112417716451
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
107403
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-5879
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-3757
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
13532000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
14805000
Quarters > 0 > balance Sheet > property Plant Equipment
250000
Quarters > 0 > balance Sheet > total Assets
16204000
Quarters > 0 > balance Sheet > payables
5634000
Quarters > 0 > balance Sheet > short Term Debt
961000
Quarters > 0 > balance Sheet > long Term Debt
21309000
Quarters > 0 > balance Sheet > total Liabilities
32450000
Quarters > 0 > balance Sheet > equity
-16246000
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
-9711.5
Quarters > 0 > cash Flow > depreciation
75.5
Quarters > 0 > cash Flow > change In Working Capital
36.5
Quarters > 0 > cash Flow > cash From Operations
-5205
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-50.5
Quarters > 0 > cash Flow > cash From Financing
7336.5
Quarters > 0 > cash Flow > net Change In Cash
-
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.09042112417716451
Quarters > 0 > ratios > PB
-1.2137874430629076
Quarters > 0 > ratios > ROE
0.05977779145635849
Quarters > 0 > ratios > ROA
-0.059932732658602814
Quarters > 0 > ratios > FCF
-5205
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
24
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
7383
Quarters > 1 > income Statement > operating Income
-7383
Quarters > 1 > income Statement > interest Expense
3851
Quarters > 1 > income Statement > pretax Income
-11566
Quarters > 1 > income Statement > net Income
-11525
Quarters > 1 > income Statement > eps
-0.0001301995074448135
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
88518000
Quarters > 1 > income Statement > income Tax Expense
-41
Quarters > 1 > income Statement > EBITDA
-7337
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-4183
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
9503000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
201000
Quarters > 1 > balance Sheet > inventories
-201000
Quarters > 1 > balance Sheet > total Current Assets
11065000
Quarters > 1 > balance Sheet > property Plant Equipment
298000
Quarters > 1 > balance Sheet > total Assets
12521000
Quarters > 1 > balance Sheet > payables
4876000
Quarters > 1 > balance Sheet > short Term Debt
3839000
Quarters > 1 > balance Sheet > long Term Debt
8088000
Quarters > 1 > balance Sheet > total Liabilities
22283000
Quarters > 1 > balance Sheet > equity
-9762000
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
-11525
Quarters > 1 > cash Flow > depreciation
156
Quarters > 1 > cash Flow > change In Working Capital
2217
Quarters > 1 > cash Flow > cash From Operations
-14278
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-103
Quarters > 1 > cash Flow > cash From Financing
-5957
Quarters > 1 > cash Flow > net Change In Cash
-29979
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.0001301995074448135
Quarters > 1 > ratios > PB
-1664.8130301167794
Quarters > 1 > ratios > ROE
0.118059823806597
Quarters > 1 > ratios > ROA
-0.09204536378883477
Quarters > 1 > ratios > FCF
-14278
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
23
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
-
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
11290
Quarters > 2 > income Statement > operating Income
-11290
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-14349
Quarters > 2 > income Statement > net Income
-14395
Quarters > 2 > income Statement > eps
-0.00020432266709396291
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
70452291
Quarters > 2 > income Statement > income Tax Expense
46
Quarters > 2 > income Statement > EBITDA
-11132
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-3059
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
29979000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
33966000
Quarters > 2 > balance Sheet > property Plant Equipment
347000
Quarters > 2 > balance Sheet > total Assets
35460000
Quarters > 2 > balance Sheet > payables
17473000
Quarters > 2 > balance Sheet > short Term Debt
3777000
Quarters > 2 > balance Sheet > long Term Debt
8706000
Quarters > 2 > balance Sheet > total Liabilities
34081000
Quarters > 2 > balance Sheet > equity
1379000
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
-14395
Quarters > 2 > cash Flow > depreciation
158
Quarters > 2 > cash Flow > change In Working Capital
-2720
Quarters > 2 > cash Flow > cash From Operations
-4346.5
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-61.5
Quarters > 2 > cash Flow > cash From Financing
31772
Quarters > 2 > cash Flow > net Change In Cash
29979
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.00020432266709396291
Quarters > 2 > ratios > PB
9380.014958375636
Quarters > 2 > ratios > ROE
-1.043872371283539
Quarters > 2 > ratios > ROA
-0.040595036661026505
Quarters > 2 > ratios > FCF
-4346.5
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
17
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
5645
Quarters > 3 > income Statement > operating Income
-5645
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-7174.5
Quarters > 3 > income Statement > net Income
-7197.5
Quarters > 3 > income Statement > eps
-0.1021617555214898
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
70452
Quarters > 3 > income Statement > income Tax Expense
23
Quarters > 3 > income Statement > EBITDA
-5566
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-1529.5
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
29979000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
33966000
Quarters > 3 > balance Sheet > property Plant Equipment
347000
Quarters > 3 > balance Sheet > total Assets
35460000
Quarters > 3 > balance Sheet > payables
17473000
Quarters > 3 > balance Sheet > short Term Debt
3777000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
34081000
Quarters > 3 > balance Sheet > equity
1379000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-7197.5
Quarters > 3 > cash Flow > depreciation
79
Quarters > 3 > cash Flow > change In Working Capital
-1360
Quarters > 3 > cash Flow > cash From Operations
-4346.5
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
15886
Quarters > 3 > cash Flow > net Change In Cash
11405
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.1021617555214898
Quarters > 3 > ratios > PB
9.379976214648297
Quarters > 3 > ratios > ROE
-0.5219361856417695
Quarters > 3 > ratios > ROA
-0.020297518330513253
Quarters > 3 > ratios > FCF
-4346.5
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
17
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
18673
Annuals > 0 > income Statement > operating Income
-18673
Annuals > 0 > income Statement > interest Expense
3851
Annuals > 0 > income Statement > pretax Income
-25915
Annuals > 0 > income Statement > net Income
-25920
Annuals > 0 > income Statement > eps
-0.00029282179895614454
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
88518000
Annuals > 0 > income Statement > income Tax Expense
5
Annuals > 0 > income Statement > EBITDA
-18469
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-7242
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
9503000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
201000
Annuals > 0 > balance Sheet > inventories
-201000
Annuals > 0 > balance Sheet > total Current Assets
11065000
Annuals > 0 > balance Sheet > property Plant Equipment
298000
Annuals > 0 > balance Sheet > total Assets
12521000
Annuals > 0 > balance Sheet > payables
4876000
Annuals > 0 > balance Sheet > short Term Debt
3839000
Annuals > 0 > balance Sheet > long Term Debt
8088000
Annuals > 0 > balance Sheet > total Liabilities
22283000
Annuals > 0 > balance Sheet > equity
-9762000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
-25920000
Annuals > 0 > cash Flow > depreciation
315000
Annuals > 0 > cash Flow > change In Working Capital
-4598000
Annuals > 0 > cash Flow > cash From Operations
-22971000
Annuals > 0 > cash Flow > capital Expenditures
226000
Annuals > 0 > cash Flow > cash From Investing
-226000
Annuals > 0 > cash Flow > cash From Financing
25816000
Annuals > 0 > cash Flow > net Change In Cash
2627000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
-0.00029282179895614454
Annuals > 0 > ratios > PB
-1672.9738783036264
Annuals > 0 > ratios > ROE
0.265519360786724
Annuals > 0 > ratios > ROA
-0.20701221947128823
Annuals > 0 > ratios > FCF
-23197000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
15
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
28568000
Annuals > 1 > income Statement > operating Income
-28568000
Annuals > 1 > income Statement > interest Expense
2167000
Annuals > 1 > income Statement > pretax Income
-30944000
Annuals > 1 > income Statement > net Income
-30944000
Annuals > 1 > income Statement > eps
-0.3934849352390225
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
78640876
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-28371000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-2376000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
6875000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
8868000
Annuals > 1 > balance Sheet > property Plant Equipment
204000
Annuals > 1 > balance Sheet > total Assets
10220000
Annuals > 1 > balance Sheet > payables
8971000
Annuals > 1 > balance Sheet > short Term Debt
3638000
Annuals > 1 > balance Sheet > long Term Debt
9423000
Annuals > 1 > balance Sheet > total Liabilities
25381000
Annuals > 1 > balance Sheet > equity
-15161000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
-30944000
Annuals > 1 > cash Flow > depreciation
346000
Annuals > 1 > cash Flow > change In Working Capital
3244000
Annuals > 1 > cash Flow > cash From Operations
-23806000
Annuals > 1 > cash Flow > capital Expenditures
123000
Annuals > 1 > cash Flow > cash From Investing
-123000
Annuals > 1 > cash Flow > cash From Financing
23983000
Annuals > 1 > cash Flow > net Change In Cash
-114000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-0.3934849352390225
Annuals > 1 > ratios > PB
-957.0108582547325
Annuals > 1 > ratios > ROE
204.1026317525229
Annuals > 1 > ratios > ROA
-302.7788649706458
Annuals > 1 > ratios > FCF
-23929000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
27425000
Annuals > 2 > income Statement > operating Income
-27426000
Annuals > 2 > income Statement > interest Expense
1400000
Annuals > 2 > income Statement > pretax Income
-28730000
Annuals > 2 > income Statement > net Income
-28730000
Annuals > 2 > income Statement > eps
-0.43032290334264583
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
66763818
Annuals > 2 > income Statement > income Tax Expense
1304000
Annuals > 2 > income Statement > EBITDA
-27057000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-1304000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
6990000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
905000
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
9730000
Annuals > 2 > balance Sheet > property Plant Equipment
327000
Annuals > 2 > balance Sheet > total Assets
11271000
Annuals > 2 > balance Sheet > payables
6014000
Annuals > 2 > balance Sheet > short Term Debt
2004000
Annuals > 2 > balance Sheet > long Term Debt
11102000
Annuals > 2 > balance Sheet > total Liabilities
22747000
Annuals > 2 > balance Sheet > equity
-11476000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
-28730000
Annuals > 2 > cash Flow > depreciation
300000
Annuals > 2 > cash Flow > change In Working Capital
4766000
Annuals > 2 > cash Flow > cash From Operations
-22993000
Annuals > 2 > cash Flow > capital Expenditures
385000
Annuals > 2 > cash Flow > cash From Investing
-385000
Annuals > 2 > cash Flow > cash From Financing
23478000
Annuals > 2 > cash Flow > net Change In Cash
137000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-0.43032290334264583
Annuals > 2 > ratios > PB
-1073.3639265423492
Annuals > 2 > ratios > ROE
250.34855350296272
Annuals > 2 > ratios > ROA
-254.9019607843137
Annuals > 2 > ratios > FCF
-23378000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
21108000
Annuals > 3 > income Statement > operating Income
-21108000
Annuals > 3 > income Statement > interest Expense
235000
Annuals > 3 > income Statement > pretax Income
-21178000
Annuals > 3 > income Statement > net Income
-21194000
Annuals > 3 > income Statement > eps
-0.34564663171972754
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
61316958
Annuals > 3 > income Statement > income Tax Expense
16000
Annuals > 3 > income Statement > EBITDA
-20973000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-70000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
6853000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
1418000
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
12023000
Annuals > 3 > balance Sheet > property Plant Equipment
207000
Annuals > 3 > balance Sheet > total Assets
13182000
Annuals > 3 > balance Sheet > payables
2229000
Annuals > 3 > balance Sheet > short Term Debt
613000
Annuals > 3 > balance Sheet > long Term Debt
2918000
Annuals > 3 > balance Sheet > total Liabilities
10264000
Annuals > 3 > balance Sheet > equity
2918000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-21194000
Annuals > 3 > cash Flow > depreciation
307000
Annuals > 3 > cash Flow > change In Working Capital
-1761000
Annuals > 3 > cash Flow > cash From Operations
-22218000
Annuals > 3 > cash Flow > capital Expenditures
474000
Annuals > 3 > cash Flow > cash From Investing
-473000
Annuals > 3 > cash Flow > cash From Financing
25590000
Annuals > 3 > cash Flow > net Change In Cash
2745000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-0.34564663171972754
Annuals > 3 > ratios > PB
3876.9632457162443
Annuals > 3 > ratios > ROE
-726.3193968471555
Annuals > 3 > ratios > ROA
-160.7798513123957
Annuals > 3 > ratios > FCF
-22692000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
9
Valuation > metrics > PE
-0.09042112417716451
Valuation > metrics > PB
-1.2137874430629076
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
0.05977779145635849
Profitability > metrics > ROA
-0.06559608240459305
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-1.5851191268467988
Risk > final Score
24
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.244882486732373
Liquidity > metrics > Quick Ratio
2.244882486732373
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
22
Prev Risks > 1
-8
Prev Risks > 2
-8
Prev Liquidities > 0
82
Prev Liquidities > 1
90
Prev Liquidities > 2
90
Updated At
2026-01-20T23:01:17.716Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-26
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-27
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
AfterMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.18
Earnings History > 1 > eps Estimate
-0.99
Earnings History > 1 > eps Difference
0.81
Earnings History > 1 > surprise Percent
81.8182
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-03-31
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-
Earnings History > 2 > eps Estimate
-0.06
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-02-27
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.11
Earnings History > 3 > eps Estimate
-0.23
Earnings History > 3 > eps Difference
0.12
Earnings History > 3 > surprise Percent
52.1739
Earnings History > 4 > period
2022-12-31
Earnings History > 4 > report Date
2023-03-02
Earnings History > 4 > date
2022-12-31
Earnings History > 4 > before After Market
BeforeMarket
Earnings History > 4 > currency
EUR
Earnings History > 4 > eps Actual
0
Earnings History > 4 > eps Estimate
-0.18
Earnings History > 4 > eps Difference
0.18
Earnings History > 4 > surprise Percent
100
Earnings History > 5 > period
2022-06-30
Earnings History > 5 > report Date
2022-08-25
Earnings History > 5 > date
2022-06-30
Earnings History > 5 > before After Market
BeforeMarket
Earnings History > 5 > currency
EUR
Earnings History > 5 > eps Actual
0
Earnings History > 5 > eps Estimate
-0.22
Earnings History > 5 > eps Difference
0.22
Earnings History > 5 > surprise Percent
100
Earnings History > 6 > period
2021-12-31
Earnings History > 6 > report Date
2022-03-25
Earnings History > 6 > date
2021-12-31
Earnings History > 6 > before After Market
AfterMarket
Earnings History > 6 > currency
EUR
Earnings History > 6 > eps Actual
0
Earnings History > 6 > eps Estimate
-0.1
Earnings History > 6 > eps Difference
0.1
Earnings History > 6 > surprise Percent
100
Earnings History > 7 > period
2021-06-30
Earnings History > 7 > report Date
2021-08-26
Earnings History > 7 > date
2021-06-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
EUR
Earnings History > 7 > eps Actual
0
Earnings History > 7 > eps Estimate
-0.2
Earnings History > 7 > eps Difference
0.2
Earnings History > 7 > surprise Percent
100
Earnings History > 8 > period
2020-12-31
Earnings History > 8 > report Date
2021-03-25
Earnings History > 8 > date
2020-12-31
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
EUR
Earnings History > 8 > eps Actual
0
Earnings History > 8 > eps Estimate
-0.1
Earnings History > 8 > eps Difference
0.1
Earnings History > 8 > surprise Percent
100
Earnings History > 9 > period
2019-03-31
Earnings History > 9 > report Date
2019-05-07
Earnings History > 9 > date
2019-03-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
EUR
Earnings History > 9 > eps Actual
0
Earnings History > 9 > eps Estimate
-0.19
Earnings History > 9 > eps Difference
0.19
Earnings History > 9 > surprise Percent
100
Earnings History > 10 > period
2018-06-30
Earnings History > 10 > report Date
2018-09-13
Earnings History > 10 > date
2018-06-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
EUR
Earnings History > 10 > eps Actual
0
Earnings History > 10 > eps Estimate
-0.39
Earnings History > 10 > eps Difference
0.39
Earnings History > 10 > surprise Percent
100
Earnings History > 11 > period
2018-03-31
Earnings History > 11 > report Date
2018-05-21
Earnings History > 11 > date
2018-03-31
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
EUR
Earnings History > 11 > eps Actual
-0.26
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
-0.26
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2017-12-31
Earnings History > 12 > report Date
2018-03-27
Earnings History > 12 > date
2017-12-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
EUR
Earnings History > 12 > eps Actual
-0.76
Earnings History > 12 > eps Estimate
-0.4
Earnings History > 12 > eps Difference
-0.36
Earnings History > 12 > surprise Percent
-90
Earnings History > 13 > period
2017-06-30
Earnings History > 13 > report Date
2017-09-06
Earnings History > 13 > date
2017-06-30
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
EUR
Earnings History > 13 > eps Actual
-0.26
Earnings History > 13 > eps Estimate
-0.3
Earnings History > 13 > eps Difference
0.04
Earnings History > 13 > surprise Percent
13.3333
Earnings History > 14 > period
2016-06-30
Earnings History > 14 > report Date
2016-08-04
Earnings History > 14 > date
2016-06-30
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
EUR
Earnings History > 14 > eps Actual
-0.16
Earnings History > 14 > eps Estimate
0
Earnings History > 14 > eps Difference
-0.16
Earnings History > 14 > surprise Percent
-
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, it develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Stock Price
GBp 0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AUK Growth Stocks With High Insider Ownership To Watch simplywall.st
Read more →Showing 2 of 9
(Last Updated 2025-06-30)
Rating:
BUY
$
Analyst Picks
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
* Institutions hold a combined 0.00% of the total shares of Faron Pharmaceuticals Oy
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2025-06-30
EPS Actual
-0.18
EPS Estimate
-0.99
EPS Difference
0.81
Surprise Percent
81.8182%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
£ 0
Cost Of Revenue
£ 0
Gross Profit
£ 0
Operating Expenses
£ 0
Operating Income
£ 0
Interest Expense
£ 0
Pretax Income
£ 0
Net Income
£ 0
Income Tax Expense
£ 0
EBITDA
£ 0
Total Other Income Expense Net
£ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
£ 0
Short Term Investments
£ 0
Receivables
£ 0
Inventories
£ 0
Total Current Assets
£ 0
Property Plant Equipment
£ 0
Total Assets
£ 0
Payables
£ 0
Short Term Debt
£ 0
Long Term Debt
£ 0
Total Liabilities
£ 0
Equity
£ 0
(Last Updated 2025-06-30)
Net Income
£ 0
Depreciation
£ 0
Change In Working Capital
£ 0
Cash From Operations
£ 0
Capital Expenditures
£ 0
Cash From Investing
£ 0
Cash From Financing
£ 0
Net Change In Cash
£ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.